Early progression of disease within 24 months(POD24)of diagnosis is associated with inferior overall survival(OS)in follicular lymphoma,but its prognostic role in Waldenström’s macroglobulinemia(WM)is still uncl...Early progression of disease within 24 months(POD24)of diagnosis is associated with inferior overall survival(OS)in follicular lymphoma,but its prognostic role in Waldenström’s macroglobulinemia(WM)is still unclear.Here,we per-formed a retrospective analysis of 373 patients pooled from the database of the Chinese Registration Network for WM(CRNWM)to determine the outcomes of early progressors.POD24 occurred in 98 evaluable patients(26.3%).The median OS in patients with POD24 was 40 months(95%CI:15.2–64.0),which was significantly shorter than that with-out POD24(156 months,95%CI:123.6–188.4;HR:6.587,95%CI 4.392–9.881,P<0.0001).Moreover,subgroup analysis showed that POD24 still maintained its predictive ability of inferior OS in patients treated with rituximab or borte-zomib-based treatment.Patients with a very high-risk rIPSSWM stage were more likely to have POD24(P=0.020).In conclusion,POD24 was associated with poorer survival and may represent a useful endpoint in future prospective clinical trials.展开更多
基金supported by grants from the National Nature Science Foundation of China(82370197,81900203,81970187,82170193 and 81920108006)Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(2022-I2M-1-022 and 2021-I2M-C&T-B-081).
文摘Early progression of disease within 24 months(POD24)of diagnosis is associated with inferior overall survival(OS)in follicular lymphoma,but its prognostic role in Waldenström’s macroglobulinemia(WM)is still unclear.Here,we per-formed a retrospective analysis of 373 patients pooled from the database of the Chinese Registration Network for WM(CRNWM)to determine the outcomes of early progressors.POD24 occurred in 98 evaluable patients(26.3%).The median OS in patients with POD24 was 40 months(95%CI:15.2–64.0),which was significantly shorter than that with-out POD24(156 months,95%CI:123.6–188.4;HR:6.587,95%CI 4.392–9.881,P<0.0001).Moreover,subgroup analysis showed that POD24 still maintained its predictive ability of inferior OS in patients treated with rituximab or borte-zomib-based treatment.Patients with a very high-risk rIPSSWM stage were more likely to have POD24(P=0.020).In conclusion,POD24 was associated with poorer survival and may represent a useful endpoint in future prospective clinical trials.
